Portugal built its reputation as the EU's primary GMP processing hub on a combination of favorable climate, relatively accessible licensing, and the practical reality that a disproportionate share of prescription flower reaching German and British pharmacies either originated from or passed through its facilities. A new Whitney Economics report on EU cannabis market dynamics finds that position under serious pressure - from domestic enforcement fallout, a more crowded international supply picture, and a Czech Republic that is actively positioning itself to absorb processing activity that Portugal can no longer reliably handle.
When Enforcement Lands on the Compliant
The trigger was Operation Erva Daninha, an enforcement action that exposed bad actors within the Portuguese cannabis industry. What followed, though, extended well beyond the specific operators involved. Infarmed's regulatory posture tightened across the board. Rebecca Allen Tapp, Managing Director of RT Consulting Solutions and contributor of the Portugal section of the Whitney Economics report, puts it plainly: "Administrative missteps that would previously have drawn a warning now risk temporary license suspensions, and the elevated scrutiny is landing on compliant operators as much as on bad actors."
That's a material operational risk for any business running GMP-certified processing for third parties. A temporary suspension doesn't just cost a processing slot - it can disrupt supply agreements, trigger batch holds, and damage relationships with offtake partners in Germany and the UK who are already managing compressed timelines and increasingly thin margins. "Many operators who have made every effort to comply are finding themselves caught in the crossfire of an industry narrative shaped by the actions of a few," Tapp says. The economics of third-party GMP service provision were already tightening; regulatory unpredictability makes the model harder to defend to investors and clients alike.
There's a structural shift under way on the supply side, too. More operators are building GMP capabilities in-house rather than relying on service providers - and some are now offering those capabilities externally, effectively becoming competitors. Tapp sees consolidation coming: "Vertically integrated operators will be better positioned to retain margin and remain agile as prices fall and the number of SKUs on the market continues to rise." That observation lands with more force when you consider the commercial reality those operators are managing. Prescription flower in Germany is available for as little as €2.59. UK flower starts around £3.50. A half-gram vape cartridge in the UK - once effectively inaccessible to private patients on cost grounds - now opens around £22, approaching what recreational consumers pay in legal US states. Margin compression isn't a future risk. It's already structural.
Czechia Steps Into the Processing Gap
Portugal's competitive position is further complicated by the fact that its export figures have always obscured something: the country functions substantially as a processing center for internationally sourced material rather than a pure cultivation hub. Latin America, South Africa, Canada, and the ANZ region are all active in the same export markets. That context matters because it means Portugal's processing advantage was always partially separable from its cultivation activity - and therefore transferable.
Czechia appears to be making that transfer. Lukas Hurt, Editor-in-Chief and Publisher of Magazine Konopí and contributor of the Czech section of the Whitney Economics report, notes that multiple representatives of new Czech GMP processing facilities were present at the Spring 2026 ICBC in Berlin. "Portugal previously absorbed much of this activity, but difficulties there have pushed producers and importers to look elsewhere," he says.
The Czech domestic market cannot sustain serious production volume on its own. Approximately 15,000 patients are currently registered in a country of 10.5 million - well below the realistic addressable population for chronic pain and neurological conditions alone, estimated at around 250,000. Between 2013 and 2024, fewer than 250 physicians held prescribing licenses, which kept the market artificially constrained. Regulatory reform in April 2025 extended prescribing rights to GPs for chronic pain, the number of active prescribers has risen sharply since, and the Czech medical cannabis market grew 46% in 2025 - its strongest performance since 2021. Still, domestic consumption sat under half a tonne of dried flower and extracts in 2025. That's not a base that sustains meaningful production scale. "Every serious Czech cultivator is focused on export, primarily within the EU," Hurt says.
Approximately ten producers now operate under SÚKL requirements, up from a single licensed producer between 2013 and 2022. The volume they are building toward is largely external. Whether they can hold that position is an open question. "The harder question is whether they can hold their ground as lower-cost suppliers from Thailand and Latin America continue to scale," Hurt says. Home cultivation of up to three plants was legalized in Czechia effective January 1, 2026, and retailers and distributors of cultivation supplies and seeds have reported significant sales increases since - a secondary market dynamic worth watching for anyone tracking consumer behavior patterns in newly liberalized European markets.
Spain: Built for Export, Struggling to Serve Its Own Patients
Spain's position in this supply network runs in a different direction entirely - and illustrates a different kind of structural problem. The country is one of the world's leading producers of medicinal cannabis, almost entirely for export. Royal Decree 903/2025 established the first clear legal framework for domestic medicinal cannabis use, covering severe refractory epilepsy, refractory chronic pain, spasticity associated with MS, and chemotherapy-induced nausea. Patients accessing through the public hospital system pay only the standard pharmaceutical copayment.
Here's the catch: the commercial infrastructure built by AEMPS-authorized companies spent years optimizing for German, Portuguese, Polish, and UK demand. It was not built with Spanish patients in mind. Carola Pérez, Founder of Dosemociones and the Spanish Observatory for Medical Cannabis and co-founder of We, The Patients - and contributor of the Spain section of the report - frames it directly: "We have built one of Europe's largest production bases, and we built it for someone else's patients."
The decree itself has limitations that matter operationally. Flower is excluded. So are pastilles and suppositories - formats that are therapeutically appropriate for a portion of the patient population the decree is meant to serve. AEMPS still operates through largely manual licensing processes, without a public registry of authorizations. Implementation depends on each autonomous community choosing to fund the model and on individual hospitals having both budget and trained specialists. Those conditions vary enough across Spain's regions to produce uneven access in practice. Tens of thousands of Spanish patients remain in grey channels.
"Transparency is not a governance nicety; it is market infrastructure. Investors and patients alike need to see the rules," Pérez says. That framing applies equally to the GMP supply chain running across the EU. When enforcement is opaque, when licensing registries are inaccessible, and when regulatory responses to isolated bad actors sweep up compliant operators, the whole system absorbs the friction - not just the wrongdoers. Medium-term projections place a functioning Spanish medical system within two to three years, if implementation holds. Whether Portuguese GMP operators recover their footing in the same window is a question the Whitney Economics report leaves open. The direction of pressure, though, is clear enough.
